The vagus nerve and the nicotinic anti-inflammatory pathway

377Citations
Citations of this article
239Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Physiological anti-inflammatory mechanisms are selected by evolution to effectively control the immune system and can be exploited for the treatment of inflammatory disorders. Recent studies indicate that the vagus nerve (which is the longest of the cranial nerves and innervates most of the peripheral organs) can modulate the immune response and control inflammation through a 'nicotinic anti-inflammatory pathway' dependent on the α7-nicotinic acetylcholine receptor (α7nAChR). Nicotine has been used in clinical trials for the treatment of ulcerative colitis, but its clinical applications are limited by its unspecific effects and subsequent toxicity. This article reviews recent advances supporting the therapeutic potential of selective nicotinic agonists in several diseases. Similar to the development of α- and β-agonists for adrenoceptors, selective agonists for α7nAChR could represent a promising pharmacological strategy against infectious and inflammatory diseases.

Cite

CITATION STYLE

APA

Ulloa, L. (2005, August). The vagus nerve and the nicotinic anti-inflammatory pathway. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd1797

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free